Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: Rich Scharf who wrote (80078)	2/29/2000 9:56:00 AM
From: marquis103	Respond to of 108040

INTA. Pushing 10. On comeback trail the past few days. Russ

To: Rich Scharf who wrote (80078)	2/29/2000 10:12:00 AM
From: Raj Ramaswamy	Respond to of 108040

JMAR: The Nasdaq rally might or might not be losing steam, but two areas, semiconductors and biotechnology, are still hot as an Arabian lunch hour. Indeed, researchers at the University of California at Berkeley are saying they have formed what they believe is the first "bionic chip," part living tissue and part machine. See the campus news release. Bionic circuitry could "be useful for developing body implants for treatment of genetic diseases," Boris Rubinsky, the mechanical engineering professor who worked on the new device, said in the statement. One company that might benefit from the combination, JMAR Technologies (JMAR: news, msgs) of San Diego, has been transforming some of its semiconductor fabrication plants into biochip factories. JMAR, which operates several companies, states that it owns precision equipment and optical measurement systems "for the rapidly expanding DNA biochip market." Lately, JMAR shares on Nasdaq have been rising rapidly on swelling volume. The stock rose 2 to 13 3/16 Monday morning, up from 5 1/2 at the start of the year and giving it a market capitalization of $240 million. JMAR's materials state it develops imaging tools that examine polymer and biological cell structures. The company last month said it received orders valued at about $1.8 million from "a leading DNA biochip company" for JMAR's lithography alignment systems.